Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1855 1
1867 1
1886 1
1920 1
1921 2
1922 1
1926 1
1927 1
1928 1
1929 1
1930 2
1935 1
1939 1
1947 1
1950 2
1951 4
1952 3
1953 1
1954 1
1955 5
1956 2
1957 1
1958 3
1959 1
1960 3
1961 5
1962 8
1963 2
1964 4
1965 4
1966 14
1967 4
1968 2
1969 11
1970 4
1971 12
1972 5
1973 13
1974 15
1975 27
1976 23
1977 31
1978 38
1979 33
1980 32
1981 62
1982 68
1983 83
1984 74
1985 96
1986 123
1987 114
1988 119
1989 139
1990 137
1991 162
1992 207
1993 192
1994 183
1995 189
1996 210
1997 222
1998 248
1999 283
2000 340
2001 373
2002 346
2003 341
2004 419
2005 503
2006 500
2007 582
2008 535
2009 558
2010 549
2011 556
2012 664
2013 876
2014 1745
2015 2036
2016 2051
2017 2049
2018 2270
2019 2648
2020 3361
2021 2760
Text availability
Article attribute
Article type
Publication date

Search Results

26,808 results
Results by year
Filters applied: . Clear all The following term was not found in PubMed: Aljari
Page 1
Targeting metastatic cancer.
Ganesh K, Massagué J. Ganesh K, et al. Nat Med. 2021 Jan;27(1):34-44. doi: 10.1038/s41591-020-01195-4. Epub 2021 Jan 13. Nat Med. 2021. PMID: 33442008 Free PMC article. Review.
Autophagy and Mitophagy in Cardiovascular Disease.
Bravo-San Pedro JM, Kroemer G, Galluzzi L. Bravo-San Pedro JM, et al. Circ Res. 2017 May 26;120(11):1812-1824. doi: 10.1161/CIRCRESAHA.117.311082. Circ Res. 2017. PMID: 28546358 Review.
Anti-hypernociceptive and anti-inflammatory effects of JM-20: A novel hybrid neuroprotective compound.
Garrido-Suárez BB, Garrido G, Castro-Labrada M, Merino N, Valdés O, Pardo Z, Ochoa-Rodríguez E, Verdecia-Reyes Y, Delgado-Hernández R, Godoy-Figueiredo J, Ferreira SH. Garrido-Suárez BB, et al. Brain Res Bull. 2020 Dec;165:185-197. doi: 10.1016/j.brainresbull.2020.10.003. Epub 2020 Oct 20. Brain Res Bull. 2020. PMID: 33096198
It further introduces JM-20 in a chronic constriction injury (CCI) model to clarify the possible subjacent mechanisms with its consequent clinical relevance. ...JM-20 reduced in vivo neutrophil migration, rolling and adhesion to the endothelium induced by intraperit …
It further introduces JM-20 in a chronic constriction injury (CCI) model to clarify the possible subjacent mechanisms with its conseq …
JM-20 protects memory acquisition and consolidation on scopolamine model of cognitive impairment.
Wong-Guerra M, Jiménez-Martin J, Fonseca-Fonseca LA, Ramírez-Sánchez J, Montano-Peguero Y, Rocha JB, D Avila F, de Assis AM, Souza DO, Pardo-Andreu GL, Del Valle RM, Lopez GA, Martínez OV, García NM, Mondelo-Rodríguez A, Padrón-Yaquis AS, Nuñez-Figueredo Y. Wong-Guerra M, et al. Neurol Res. 2019 May;41(5):385-398. doi: 10.1080/01616412.2019.1573285. Epub 2019 Mar 1. Neurol Res. 2019. PMID: 30821663
However, the neuroprotective effect of JM-20 against memory impairment in preclinical AD-like models has not been analyzed. ...METHODS: The effects of JM-20 on scopolamine (1 mg/kg)-induced cognitive disorders were studied. ...
However, the neuroprotective effect of JM-20 against memory impairment in preclinical AD-like models has not been analyzed. ...METHOD …
Effects of topical and intravenous JM-1232(-) infusion on cerebrovascular reactivity in rats.
Iwata K, Iida H, Iida M, Fukuoka N, Kito K, Tanabe K. Iwata K, et al. J Anesth. 2015 Oct;29(5):798-802. doi: 10.1007/s00540-015-2017-9. Epub 2015 Apr 26. J Anesth. 2015. PMID: 25913256
Therefore, we investigated the cerebrovascular reactivity to topical and intravenous JM-1232(-) and during hypotension or hypercapnia with intravenous administration of JM-1232(-). ...Finally, we measured the reaction to stepwise induction of hypotension before and …
Therefore, we investigated the cerebrovascular reactivity to topical and intravenous JM-1232(-) and during hypotension or hypercapnia …
JM-20, a novel hybrid molecule, protects against rotenone-induced neurotoxicity in experimental model of Parkinson's disease.
Fonseca-Fonseca LA, Wong-Guerra M, Ramírez-Sánchez J, Montano-Peguero Y, Padrón Yaquis AS, Rodríguez AM, da Silva VDA, Costa SL, Pardo-Andreu GL, Núñez-Figueredo Y. Fonseca-Fonseca LA, et al. Neurosci Lett. 2019 Jan 18;690:29-35. doi: 10.1016/j.neulet.2018.10.008. Epub 2018 Oct 7. Neurosci Lett. 2019. PMID: 30304707
The aim of this study was to investigate the effects of a novel hybrid molecule, named JM-20, in different in vitro and in vivo models of PD induced by rotenone. To perform in vitro studies, SHSY-5Y cells were exposed to rotenone and/or treated with JM-20. To perfor …
The aim of this study was to investigate the effects of a novel hybrid molecule, named JM-20, in different in vitro and in vivo model …
Neuroprotection by JM-1232(-) against oxygen-glucose deprivation-induced injury in rat hippocampal slice culture.
Ogura T, Hamada T, Matsui T, Tanaka S, Okabe S, Kazama T, Kobayashi Y. Ogura T, et al. Brain Res. 2015 Jan 12;1594:52-60. doi: 10.1016/j.brainres.2014.10.038. Epub 2014 Oct 31. Brain Res. 2015. PMID: 25451121
JM-1232(-) (JM) is a novel isoindoline derivative with sedative and hypnotic activities that are mediated by binding to the benzodiazepine site of the Gamma-aminobutyric acid type A (GABAA) receptor. ...Hippocampal slices were assigned to either control or JM
JM-1232(-) (JM) is a novel isoindoline derivative with sedative and hypnotic activities that are mediated by binding to the be
JM-1232(-) and propofol, a new combination of hypnotics with short-acting and non-cumulative preferable properties.
Taharabaru S, Tamura T, Higashi M, Matsuda N, Satomoto M, Adachi YU, Sato AB, Okuda M. Taharabaru S, et al. Exp Anim. 2021 Feb 6;70(1):101-107. doi: 10.1538/expanim.20-0071. Epub 2020 Oct 16. Exp Anim. 2021. PMID: 33071272 Free PMC article.
The pharmacological advantages of a new combination of the benzodiazepine receptor agonist JM-1232(-) and propofol were investigated in mice. Male adult mice were administered JM-1232(-) or propofol or combinations of the two drugs intravenously. ...The ED(50) value …
The pharmacological advantages of a new combination of the benzodiazepine receptor agonist JM-1232(-) and propofol were investigated …
Multi-targeting effects of a new synthetic molecule (JM-20) in experimental models of cerebral ischemia.
Nuñez-Figueredo Y, Ramírez-Sánchez J, Pardo Andreu GL, Ochoa-Rodríguez E, Verdecia-Reyes Y, Souza DO. Nuñez-Figueredo Y, et al. Pharmacol Rep. 2018 Aug;70(4):699-704. doi: 10.1016/j.pharep.2018.02.013. Epub 2018 Feb 12. Pharmacol Rep. 2018. PMID: 29933207 Review.
Herein, we reviewed the main pre-clinical results of the neuroprotective effects of JM-20, a new hybrid molecule, against brain ischemia. JM-20 appears to protect the brain from ischemic damage by interfering with several elements of the ischemic cascade: antiexcito …
Herein, we reviewed the main pre-clinical results of the neuroprotective effects of JM-20, a new hybrid molecule, against brain ische …
JM-20 protects against 6-hydroxydopamine-induced neurotoxicity in models of Parkinson's disease: Mitochondrial protection and antioxidant properties.
Fonseca-Fonseca LA, da Silva VDA, Wong-Guerra M, Ramírez-Sánchez J, Yaquis ASP, Ochoa-Rodríguez E, Verdecia-Reyes Y, de Araújo FM, Santana RC, Outeiro TF, Costa SL, Núñez-Figueredo Y. Fonseca-Fonseca LA, et al. Neurotoxicology. 2021 Jan;82:89-98. doi: 10.1016/j.neuro.2020.11.005. Epub 2020 Nov 21. Neurotoxicology. 2021. PMID: 33232743
Treatment with JM-20 significantly reduced the percentage of motor asymmetry and increased vertical exploration. ...Altogether, these results demonstrate that JM-20 is a potential neuroprotective agent against 6-OHDA-induced damage in both in vitro and in vivo model …
Treatment with JM-20 significantly reduced the percentage of motor asymmetry and increased vertical exploration. ...Altogether, these …
26,808 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page